Table 2 Acute lymphoblastic leukemia with recurrent cytogenetic abnormalities
From: miR-155 and miR-92 levels in ALL, post-transplant aGVHD, and CMV: possible new treatment options
Cytogenetic abnormalities | No. of patients (%) |
|---|---|
t (9;22) BCR/ABL | 13 (18.5%) |
t (12;21) TEL/AML1 | 6 (8.5%) |
t (1;19) E2A/PBX1 | 4 (5.7%) |